A “DNA printer” is the hardware that turns digital DNA code into physical molecules, and it is the exact piece of machinery the Imperium pitch depends on. The analogy in the presentation is explicit: if DNA is software, then something has to be the printer that writes the code onto a physical medium. Adam O’Dell points at two companies that fill that role in different ways, and understanding the difference between them is the key to understanding the pitch.
The Printer: Twist Bioscience (TWST)
Twist Bioscience (TWST) is the “silicon layer” of the pitch, the Intel of the DNA revolution, and its NanoWell technology is the printer in the literal sense. Twist synthesizes DNA on silicon chips rather than in test tubes, writing thousands of sequences in parallel onto a chip the way a semiconductor fab writes circuits. The presentation claims this “processes DNA at 10,000 times the speed of the previous technology.” Our analysis could not independently verify that 10,000-times figure, which is best treated as a marketing number, but the underlying approach, synthesizing DNA on chips at scale, is real and is why Twist has landed customers like Amazon, Microsoft, Johns Hopkins, Illumina, and DARPA.
The business behind the printer is steady. Twist has posted 15 consecutive quarters of roughly 20% revenue growth, carries a market cap near $7.6 billion, and sits near break-even on an adjusted cash-flow basis. For the full investment case, see our Twist Bioscience stock piece.
The Factory: Ginkgo Bioworks (DNA)
Ginkgo Bioworks (DNA) represents the other half of the metaphor. Where Twist writes the code, Ginkgo runs it. Ginkgo’s autonomous “DNA factories” are robotic lab equipment that runs DNA-driven experiments for AI and pharma companies, essentially a printer that does not just write the sequence but executes the experiment around it. Founded by five MIT PhDs, Ginkgo was worth roughly $20 billion at its 2021 SPAC-era peak and now sits near $539 million after pivoting from custom molecules to this autonomous-lab business. Its first such sale went to Novo Nordisk, with new government wins at ARPA-H and the NSF. We dig into that turnaround in our Ginkgo Bioworks stock piece.
The Software Metaphor
The DNA-as-software idea ties the two together. “Once you can read, design, and write the code of living things,” the pitch runs, “every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.” In that framing, Twist is the printer and Ginkgo is the operating system that runs on it. The “We’re Intel, they’re Microsoft” line, originally a Twist CEO quote from 2015, captures the intended division of labor.
Why It Matters
O’Dell’s credibility on early platform calls is part of why this pitch keeps coming back. He began teasing Palantir in the spring of 2024 when the stock was in the $20s, and it became the best-performing stock in the S&P 500 for that year. The DNA printer story is a longer, more speculative arc, but the hardware itself is real and improving. If you want to understand the write step in more detail, our DNA synthesis explainer covers how the chemistry works.
Why Silicon Chips Matter
The reason Twist’s silicon approach is significant is density. A silicon chip can pack thousands of tiny reaction wells into a small area, so thousands of DNA sequences can be written in parallel on a single device. That is the same idea that made semiconductors powerful, many small features packed densely onto one chip, and it is why the presentation reaches for the “Intel of the DNA revolution” framing. The “10,000 times faster” figure is a marketing number we could not verify, but the density argument underneath it is real.
The Intel and Microsoft Division
The pitch maps the printer and the factory onto the personal-computer era. Twist is Intel, the silicon underneath. Ginkgo Bioworks is Microsoft, the software on top. The “We’re Intel, they’re Microsoft” line, originally a Twist CEO quote from 2015, captures the intended split: one company makes the physical layer, the other makes it programmable. It is a clean story, though the reality is messier, since the two companies sell to overlapping customers rather than into a single locked-together stack.
The Offer and the Track Record
The pitch is “Imperium: The No. 1 Investment for 2027,” $297 a year with a 30-day refund, and it teases Twist around $112, Ginkgo around $8.32, and Absci around $7.58. O’Dell, the chief investment strategist at Money & Markets, runs Cycle 9 Alert and 10X Profits alongside Green Zone Fortunes, and his method leans on the Green Zone Power Ratings, a quantitative screen of momentum, value, and volatility. His best recent call is documented: he began teasing Palantir in the spring of 2024 in the $20s, and it became the best-performing stock in the S&P 500 for the year.
Why It Matters Now
The DNA printer is the reason the whole thesis can move forward. Every application in the pitch, from drug discovery to data storage, starts with someone printing DNA. As the printers get faster and cheaper, the applications get cheaper too, and that feedback loop is the actual engine of the Imperium story.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.